146 related articles for article (PubMed ID: 30931812)
1. Clinical features and treatment of patients with lung adenocarcinoma with bone marrow metastasis.
Wang D; Luo Y; Shen D; Yang L; Liu HY; Che YQ
Tumori; 2019 Oct; 105(5):388-393. PubMed ID: 30931812
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
3. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Analysis of Small Cell Lung Cancer with Bone Marrow Metastases].
Che Y; Luo Y; Wang D; Shen D; Yang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):403-407. PubMed ID: 29764591
[TBL] [Abstract][Full Text] [Related]
5. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
6. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
7. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
Chen L; Fu M; Zhou J; Yao Y; Zhou J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of
Kashiwabara K; Fuji S; Tsumura S; Sakamoto K
Anticancer Res; 2020 Feb; 40(2):1117-1121. PubMed ID: 32014962
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
13. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma.
Ren X; Zhang Y; Lyu Y; Jin B; Guo H; Wu J; Li X; Liu X
Cancer Biomark; 2019; 26(2):139-150. PubMed ID: 31356196
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
Anticancer Drugs; 2020 Oct; 31(9):959-965. PubMed ID: 32889898
[TBL] [Abstract][Full Text] [Related]
16. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of gastric cancer patients with bone marrow metastases.
Kim HS; Yi SY; Jun HJ; Lee J; Park JO; Park YS; Jang J; Kim HJ; Ko Y; Lim HY; Kang WK
Oncology; 2007; 73(3-4):192-7. PubMed ID: 18418012
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.
Li XY; Zhu XR; Zhang CC; Yu W; Zhang B; Shen TL; Zhang HY; Fu XL
Clin Lung Cancer; 2020 Nov; 21(6):534-544. PubMed ID: 32505632
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
20. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
